Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Longeveron completes phase I study of Lomecel-B in hypoplastic left heart syndrome

Feb. 25, 2021

FDA approves label expansion in chronic heart failure for Entresto

Feb. 17, 2021

CXCR7 as a novel therapeutic target for myocardial infarction

Feb. 17, 2021

BioCardia announces pipeline updates and milestones

Feb. 3, 2021

PERK inhibition promising for pulmonary arterial hypertension

Feb. 1, 2021

5-HT2B as a novel therapeutic target to improve microstructural remodeling post-MI

Jan. 26, 2021

MCB-613 attenuates loss of cardiac function after myocardial infarction

Jan. 21, 2021

FDA approves Verquvo for heart failure

Jan. 20, 2021

Caladrius opens phase IIb trial of CLBS-16 for coronary microvascular dysfunction

Jan. 20, 2021

LCP2 is a therapeutic target in lethal sepsis

Jan. 19, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...